Vimarsana
Biggest News Aggregation in the World

Page 2 - Nasdaq Bbio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Bbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Bbio Today - Breaking & Trending Today

BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results, Misses Estimates By $0.09 EPS - Vimarsana News

BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results, Misses Estimates By $0.09 EPS

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.09), Briefing.com reports. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $4.78 million. BridgeBio Pharma’s revenue for the […]

BridgeBio Pharma (NASDAQ:BBIO) Issues Earnings Results - Vimarsana News

BridgeBio Pharma (NASDAQ:BBIO) Issues Earnings Results

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) issued its earnings results on Thursday. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.09), Briefing.com reports. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $4.78 million. The firm’s revenue for the quarter […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Covestor Ltd - Vimarsana News

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Covestor Ltd

Covestor Ltd raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 131.5% in the third quarter, Holdings Channel.com reports. The fund owned 9,587 shares of the company’s stock after acquiring an additional 5,446 shares during the period. Covestor Ltd’s holdings in BridgeBio Pharma were worth $252,000 at the end of the most […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Brokerages - Vimarsana News

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Brokerages

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month target […]

FY2023 Earnings Estimate for BridgeBio Pharma, Inc. (NASDAQ:BBIO) Issued By Leerink Partnrs - Vimarsana News

FY2023 Earnings Estimate for BridgeBio Pharma, Inc. (NASDAQ:BBIO) Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – Research analysts at Leerink Partnrs raised their FY2023 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($3.80) per share for the year, up […]